Daniel C. Montano

Co-Founder, Chairman, President & CEO

He brings a wide range of management experience to his roles, having served as CEO of 14 operating companies in industries such as real estate, high technology, medical technology, biotechnology, food products, financial institutions, and service companies. From 1981 until 2004, Montano was a member of the Board of Directors of Helen of Troy, Ltd, a Texas company with revenue of over $450 million. He also spent 30 years as an investment banker, retiring from that business in 1998. Montano received his MBA from the University of Southern California and his undergraduate degree from California State University, Los Angeles.

John (Jack) William Jacobs Ph.D

Chief Operating Officer and Chief Scientific Officer

Dr. Jacobs, who holds similar positions with Phage Biotechnology Corporation, joined CVBT in April 2000. Previously he served as Director of Basic Research at the Hitachi Chemical Research Center in Irvine, California, and as an adjunct Professor of Biological Chemistry at University of California-Irvine’s College of Medicine.

Earlier in his career, Dr. Jacobs worked for Merck & Co. Inc. as the head of their Department of Biological Chemistry at the Merck Sharp & Dohm Research Laboratories in West Point, Pennsylvania, and as Assistant Professor of Medicine and Biochemistry at the University of Texas Health Center. Dr. Jacobs received his Ph.D. in molecular biology from the Washington University School of Medicine, and his undergraduate degree in Chemistry from Davidson College.

Mickael A. Flaa, CPA

Chief Financial Officer

Mr. Flaa, is a CPA and a retired partner from KPMG. He joined CVBT in June 2003. Prior to these positions, he served as Interim Chief Financial Officer for publicly-held Breakaway Solutions, Inc., and as Chief Financial Officer and member of the Board of Directors for Sunbelt Integrated Trade Services, Inc.

He remains involved in the management and/or Board of Directors of several additional ventures: Memson, Inc., Onnam Gaming, and Gestalt, LLC. Flaa spent 22 years in various management positions with KPMG Peat Marwick LLP, where he was elected to partnership in 1990. He worked with clients in fields including health care, technology, utilities, transportation and energy. Flaa received his undergraduate degree from Central Washington University.

Kenneth A. Thomas, Ph.D.

Vice President, Research and Development

Dr. Thomas brings to CVBT over two decades of extensive experience at Merck Research Laboratories in scientific research and pharmaceutical development of proteins and small molecular enzyme inhibitors. He is a scientific and managerial expert in biological chemistry, molecular biology cell biology and animal pharmacology spanning oncology, cardiology, endocrinology, dermatology and ophthalmology. He has over 80 publications and over 30 issued or pending patents. He has served on The Journal of Biological Chemistry editorial board and has co-organized national/international meetings on protein kinases, signal transduction, growth factors and angiogenesis.

While at Merck Thomas initiated, built and directed the pre-clinical biology programs leading to six development candidates in pro-angiogenesis and anti-angiogenesis which contributed to the development of the hepatitis B recombinant vaccine Recombivax HB.

Dr. Thomas received his Ph.D in Biochemistry from Duke University and his Bachelor of Science degree in Chemistry from the University of Delaware.